Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 578

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 578
---
falin – Pruritus                                     | ​ | ​ | ​                           | ​ |  72,475 | ​ | ​ | ​ | 52%      | ​ | ​ | ​    | ​ | 47,814 | ​ | ​ | ​ | 86%      | ​ |
| Other                                                             | ​ | ​ | ​                           | ​ |       — | ​ | ​ | ​ | N/A      | ​ | ​ | ​    | ​ |      — | ​ | ​ | ​ | (100)%   | ​ |
| Internal research and development expenses/milestone payments﻿(1) | ​ | ​ | ​                           | ​ |  36,035 | ​ | ​ | ​ | (4)%     | ​ | ​ | ​    | ​ | 37,373 | ​ | ​ | ​ | (21)%    | ​ |
| Total research and development expenses                           | ​ | ​ | ​                           | $ | 108,510 | ​ | ​ | ​ | 18%      | ​ | ​ | ​    | $ | 91,879 | ​ | ​ | ​ | 11%      | ​ |

(1) Includes milestone payments of $5.0 million and $15.0 million to Enteris for the year ended December 31, 2022.

332

TABLE OF CONTENTS

General and Administrative Expense

| ​                                               
 ​                                               | ​ 
 ​ | ​ 
 ​ | Year Ended December 31,     
 2023                        |   |        |   |   |   |          |   |       |   | ​ | ​ | 2022 |   |        |   |   |   |          |   |       |   | ​ 
 ​ |
|:------------------------------------------------|:--|:--|:----------------------------|:--|-------:|:--|:--|:--|:---------|:--|:------|:--|:--|:--|:-----|:--|-------:|:--|:--|:--|:---------|:--|:------|:--|:--|
| ​                                               | ​ | ​ | Dollar amounts in thousands |   |        |   |   |   |          |   |       |   |   |   |      |   |        |   |   |   |          |   |       |   | ​ |
| ​                                               | ​ | ​ | ​                           | ​ |